NOVN: NATALEE's Kisqali of Life

As we highlighted in our February 23, 2020 report “Kisqali’s kiss of life“, NOVN's NATALEE trial of Kisqali demonstrated the broadest indication of any CDK4/6 in breast cancer at ASCO last weekend that brings unprecedented benefits to a large swathe of lower risk patients and opens up a substantial early stage breast cancer market, most of which is exclusively accessible to Kisqali. Its extended three year treatment, leads to $10bn peak sales opportunity (20% 2022A sales) in early-stage along with the potential to double its existing sales in late stage breast cancer with its best in class, unique NCCN category 1 recommendation.